Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362591173> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4362591173 endingPage "S51" @default.
- W4362591173 startingPage "S50" @default.
- W4362591173 abstract "For patients with non-small cell lung cancer (NSCLC) presenting with brain oligometastases, the optimal treatment sequence of thoracic and metastatic treatment is not well-established. This study sought to evaluate long-term survival of patients with NSCLC with brain oligometastases who received initial treatment of the primary site lung tumor versus brain metastases. Patients with cT1-4, N0-3, M1b-c NSCLC with synchronous limited metastatic disease isolated to the brain who received systemic therapy with radical treatment (surgery, brain stereotactic radiosurgery, or lung radiation) to both the primary site and metastases in the National Cancer Database from 2010–2019 were included. Patients who received whole brain radiation therapy or palliative treatment were excluded. Long-term overall survival of patients who received initial treatment to the brain versus lung was evaluated using Kaplan-Meier analysis, Cox proportional hazards modeling, and propensity score matching, on 15 common prognostic variables including comorbidities, clinical T/N status, and the specific type of treatment to each site. Of the 1,044 patients diagnosed with NSCLC with brain oligometastases who met the study inclusion criteria, 893 (79.0%) received treatment of the brain metastases first, and 237 (21.0%) received treatment to the lung first. In unadjusted Kaplan-Meier analysis, overall survival was similar between patients who underwent initial treatment of brain metastases versus primary site. No significant difference in overall survival was found between the two groups after multivariable-adjusted Cox proportional hazards modeling (HR: 1.24, 95% CI: 0.91–1.70, p = 0.17). In a propensity score-matched analysis of 230 patients (115 in each arm), treatment sequence of brain metastases versus lung was not significantly associated with 5-year overall survival (Brain: 38.2% [95% CI: 27.5–34.4] vs Lung: 38.0% [95% CI: 29.9–44.7], p = 0.32). The findings of this study suggest that for patients presenting with NSCLC with synchronous limited metastatic disease isolated to the brain who can tolerate aggressive treatment of the primary and metastatic sites, treatment sequence does not impact overall survival." @default.
- W4362591173 created "2023-04-06" @default.
- W4362591173 creator A5001863341 @default.
- W4362591173 creator A5014036250 @default.
- W4362591173 creator A5019693329 @default.
- W4362591173 creator A5022741004 @default.
- W4362591173 creator A5075828934 @default.
- W4362591173 creator A5077223461 @default.
- W4362591173 creator A5089982004 @default.
- W4362591173 date "2023-04-01" @default.
- W4362591173 modified "2023-09-25" @default.
- W4362591173 title "17P Treatment sequence for non-small cell lung cancer with brain oligometastases does not impact overall survival" @default.
- W4362591173 doi "https://doi.org/10.1016/s1556-0864(23)00271-x" @default.
- W4362591173 hasPublicationYear "2023" @default.
- W4362591173 type Work @default.
- W4362591173 citedByCount "0" @default.
- W4362591173 crossrefType "journal-article" @default.
- W4362591173 hasAuthorship W4362591173A5001863341 @default.
- W4362591173 hasAuthorship W4362591173A5014036250 @default.
- W4362591173 hasAuthorship W4362591173A5019693329 @default.
- W4362591173 hasAuthorship W4362591173A5022741004 @default.
- W4362591173 hasAuthorship W4362591173A5075828934 @default.
- W4362591173 hasAuthorship W4362591173A5077223461 @default.
- W4362591173 hasAuthorship W4362591173A5089982004 @default.
- W4362591173 hasBestOaLocation W43625911731 @default.
- W4362591173 hasConcept C10515644 @default.
- W4362591173 hasConcept C121608353 @default.
- W4362591173 hasConcept C126322002 @default.
- W4362591173 hasConcept C143998085 @default.
- W4362591173 hasConcept C17923572 @default.
- W4362591173 hasConcept C2776256026 @default.
- W4362591173 hasConcept C2778164965 @default.
- W4362591173 hasConcept C2779013556 @default.
- W4362591173 hasConcept C2780387249 @default.
- W4362591173 hasConcept C50382708 @default.
- W4362591173 hasConcept C509974204 @default.
- W4362591173 hasConcept C71924100 @default.
- W4362591173 hasConceptScore W4362591173C10515644 @default.
- W4362591173 hasConceptScore W4362591173C121608353 @default.
- W4362591173 hasConceptScore W4362591173C126322002 @default.
- W4362591173 hasConceptScore W4362591173C143998085 @default.
- W4362591173 hasConceptScore W4362591173C17923572 @default.
- W4362591173 hasConceptScore W4362591173C2776256026 @default.
- W4362591173 hasConceptScore W4362591173C2778164965 @default.
- W4362591173 hasConceptScore W4362591173C2779013556 @default.
- W4362591173 hasConceptScore W4362591173C2780387249 @default.
- W4362591173 hasConceptScore W4362591173C50382708 @default.
- W4362591173 hasConceptScore W4362591173C509974204 @default.
- W4362591173 hasConceptScore W4362591173C71924100 @default.
- W4362591173 hasIssue "4" @default.
- W4362591173 hasLocation W43625911731 @default.
- W4362591173 hasOpenAccess W4362591173 @default.
- W4362591173 hasPrimaryLocation W43625911731 @default.
- W4362591173 hasRelatedWork W2066530402 @default.
- W4362591173 hasRelatedWork W2085417682 @default.
- W4362591173 hasRelatedWork W2166561562 @default.
- W4362591173 hasRelatedWork W2559969777 @default.
- W4362591173 hasRelatedWork W2907586692 @default.
- W4362591173 hasRelatedWork W2914105737 @default.
- W4362591173 hasRelatedWork W3031953093 @default.
- W4362591173 hasRelatedWork W4214554202 @default.
- W4362591173 hasRelatedWork W4244523620 @default.
- W4362591173 hasRelatedWork W4378550127 @default.
- W4362591173 hasVolume "18" @default.
- W4362591173 isParatext "false" @default.
- W4362591173 isRetracted "false" @default.
- W4362591173 workType "article" @default.